FDA grants EUA to antibody treatment that addresses SARS-CoV-2 variants
The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) to GlaxoSmithKline for the investigational monoclonal antibody therapy sotrovimab for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients who are at least 12 years old.
Laboratory testing showed that sotrovimab retains activity against the current circulating variants first reported in the United Kingdom, South Africa, Brazil, California, New York, and India, the FDA said.
The FDA said it did not authorize sotrovimab for patients who are hospitalized due to COVID-19 or require oxygen therapy due to COVID-19. The FDA said the treatment has not been shown to benefit patients hospitalized due to COVID-19, and monoclonal antibodies may be associated with worse clinical outcomes when administered to hospitalized patients requiring high flow oxygen or mechanical ventilation.
Sotrovimab is a monoclonal antibody — a man-made protein — that is specifically directed against the spike protein of SARS-CoV-2 and is designed to block the virus’ attachment and entry into human cells.
The data supporting this EUA for sotrovimab are based on an interim analysis from a phase 1/2/3 randomized, double-blind, placebo-controlled clinical trial in 583 non-hospitalized adults with mild-to-moderate COVID-19 symptoms and a positive SARS-CoV-2 test result. Of these patients, 291 received sotrovimab and 292 received a placebo within five days of onset of COVID-19 symptoms. The primary endpoint was progression of COVID-19 (defined as hospitalization for greater than 24 hours for acute management of any illness or death from any cause) through day 29. Hospitalization or death occurred in 21 (7%) patients who received placebo compared to 3 (1%) patients treated with sotrovimab.
